Lapatinib is classified as a signal transduction inhibitor - tyrosine kinase inhibitor, inhibitor of EGFR and HER2. Lapatinib is marketed as Tykerb and is used in the treatment of metastatic breast cancer that is HER-2 positive. The drug may also be used in combination with other chemotherapy drugs or for the treatment of other cancers.
More information
More information
Related categories 1
Last update:
March 20, 2018 at 9:24:08 UTC
Check out
Reference: Education: Colleges and Universities: Europe: United Kingdom: England: University of London: Colleges and Institutes: University College London
- Recently edited by merlin1
- Recently edited by merlin1